Identification of tiagabine degradation products using liquid chromatography with electrospray ionization multistage mass spectrometry and ultra-performance liquid chromatography/high-resolution mass spectrometry.

RATIONALE Tiagabine hydrochloride monohydrate drug substance (TGB) is an antiepileptic agent effective in the treatment of seizure disorders. The stability of TGB was studied and its degradation products were identified for the first time. METHODS TGB was heated in the presence of H(2)O(2). Degradation products were analyzed by liquid chromatography coupled to electrospray ionization multistage mass spectrometry (LC/ESI-MS(n)) and high-resolution mass spectrometry (HR-MS). RESULTS This study showed that TGB was degraded by oxidative pathways involving attack of oxygen at different centers but mainly at the double bond of the molecule. The oxidative cascade reactions initiated by the epoxidation of the double bond of tiagabine led to dihydroxy, ketohydroxy and ketone derivatives as well as bisthiophene ketone. CONCLUSIONS Nine degradation products of TGB were identified. Some diagnostic MS/MS product ions, characteristic of the piperidine or thiophene moiety, were highlighted.

[1]  A. Tan,et al.  Analyte and internal standard cross signal contributions and their impact on quantitation in LC-MS based bioanalysis. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  M. Skiba,et al.  2-Hydroxypropyl β-Cyclodextrin: A New Tool for the Improvement of Chemical Stability of Tiagabine HCl , 2009 .

[3]  M. Bartlett,et al.  Determination of degradation products of sumatriptan succinate using LC-MS and LC-MS-MS. , 2001, Journal of pharmaceutical and biomedical analysis.

[4]  J. Pedro,et al.  Nucleophilic benzoylation using lithiated methyl mandelate as a synthetic equivalent of the benzoyl carbanion. Oxidative decarboxylation of α-hydroxyacids , 2001 .

[5]  G. Anderegg,et al.  Gas chromatography-mass spectrometry assay method for the therapeutic drug monitoring of the antiepileptic drug tiagabine. , 1999, Journal of pharmaceutical and biomedical analysis.

[6]  S. Patel,et al.  Separation of the S(+) and R(-)-enantiomers of tiagabine.HCl and its two chiral precursors by chiral chromatography: application to chiral inversion studies. , 1998, Journal of pharmaceutical and biomedical analysis.

[7]  A. Rustum,et al.  Separation and quantitation of the S-(+)-enantiomer in the bulk drug tiagabine x HCl by chiral high-performance-liquid chromatography using a Chiralcel-OD column. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[8]  P. Suzdak,et al.  A Review of the Preclinical Pharmacology of Tiagabine: A Potent and Selective Anticonvulsant GABA Uptake Inhibitor , 1995, Epilepsia.

[9]  M. Brodie.  Tiagabine Pharmacology in Profile , 1995, Epilepsia.

[10]  L. Gustavson,et al.  High-performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. , 1992, Journal of chromatography.

[11]  P. Suzdak,et al.  Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. , 1991, European journal of pharmacology.

[12]  M. Nahata,et al.  Stability of tiagabine in two oral liquid vehicles. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  A. Rustum,et al.  Reversed-phase high-performance liquid chromatographic separation of the enantiomers of N-[4,4-di(3-methylthien-2-yl)-but-3-enyl] nipecotic acid on a Pirkle-type phenylglycine stationary phase , 1990 .